Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Clin Chim Acta. 2010 Dec 14;411(23-24):1920-8. doi: 10.1016/j.cca.2010.07.035. Epub 2010 Aug 14.
Spinal muscular atrophy (SMA), a lethal hereditary disease caused by mutations of the survival of motor neuron 1 (SMN1) gene, is the leading genetic cause of infant mortality. Its severity directly correlates to the expression level of SMN protein in patients with SMA, but the regulatory mechanisms of SMN protein expression remain incompletely defined. In the present study, we aimed to identify candidate proteins to distinguish SMA fibroblasts from normal fibroblasts.
To identify cellular targets regulating the expression of SMN, we initially utilized a proteomics approach combining 2D electrophoresis and LC-MS/MS, wherein the total proteins extracted from type I SMA patients and normal skin fibroblast cells were compared.
Our initial proteomics analysis discovered significant increase of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) in type I SMA fibroblasts when compared to normal fibroblasts. Significantly, UCHL1 proteins directly interacted with SMN protein, as determined by immunoprecipitation and immunofluorescence assays in P19 and NSC34 cells. Over-expression of UCHL1 in P19 and NSC34 cells significantly reduced the level of SMN proteins in vivo, and, in fact, purified UCHL1 was shown to be able to enhance, in a dose-dependent manner, the level of ubiquitinated SMN in vitro. Further, inhibition of UCHL1 activity by UCHL1 inhibitor (LDN-57444) increased cellular SMN protein and gems number in the nucleus in NSC34 and SMA skin fibroblasts. The same results were observed in cells with UCHL1-specific knockdown.
These results suggested that UCHL1 may be a critical regulator in controlling cellular SMN protein turnover, and that it may serve as an attractive therapeutic target for SMA.
脊髓性肌萎缩症(SMA)是一种致命的遗传性疾病,由运动神经元生存 1 基因(SMN1)突变引起,是婴儿死亡的主要遗传原因。其严重程度与 SMA 患者 SMN 蛋白的表达水平直接相关,但 SMN 蛋白表达的调节机制仍不完全明确。本研究旨在鉴定候选蛋白,以区分 SMA 成纤维细胞和正常成纤维细胞。
为了鉴定调节 SMN 表达的细胞靶标,我们最初采用了一种蛋白质组学方法,结合二维电泳和 LC-MS/MS,比较了来自 I 型 SMA 患者和正常皮肤成纤维细胞的总蛋白。
我们的初始蛋白质组学分析发现,与正常成纤维细胞相比,I 型 SMA 成纤维细胞中泛素羧基末端水解酶 L1(UCHL1)显著增加。重要的是,免疫沉淀和免疫荧光实验表明,UCHL1 蛋白直接与 SMN 蛋白相互作用,在 P19 和 NSC34 细胞中。UCHL1 在 P19 和 NSC34 细胞中的过表达显著降低了 SMN 蛋白的水平,事实上,纯化的 UCHL1 被证明能够以剂量依赖的方式增强体外泛素化 SMN 的水平。此外,UCHL1 抑制剂(LDN-57444)抑制 UCHL1 活性可增加 NSC34 和 SMA 皮肤成纤维细胞中细胞 SMN 蛋白和核内 gems 数量。在具有 UCHL1 特异性敲低的细胞中也观察到了相同的结果。
这些结果表明,UCHL1 可能是控制细胞 SMN 蛋白周转的关键调节剂,它可能是 SMA 的一个有吸引力的治疗靶点。